JP2017515893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515893A5 JP2017515893A5 JP2017508775A JP2017508775A JP2017515893A5 JP 2017515893 A5 JP2017515893 A5 JP 2017515893A5 JP 2017508775 A JP2017508775 A JP 2017508775A JP 2017508775 A JP2017508775 A JP 2017508775A JP 2017515893 A5 JP2017515893 A5 JP 2017515893A5
- Authority
- JP
- Japan
- Prior art keywords
- hdl
- subject
- hours
- hdl therapeutic
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 223
- 239000003814 drug Substances 0.000 claims description 117
- 229940124597 therapeutic agent Drugs 0.000 claims description 115
- 230000001225 therapeutic effect Effects 0.000 claims description 64
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 claims description 32
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 claims description 32
- 101150092476 ABCA1 gene Proteins 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 24
- 102000013010 Member 1 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 claims description 18
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 17
- 238000012423 maintenance Methods 0.000 claims description 16
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 claims description 14
- 108010002025 CER-001 Proteins 0.000 claims description 13
- 210000002540 macrophage Anatomy 0.000 claims description 13
- 210000001616 monocyte Anatomy 0.000 claims description 13
- 210000005087 mononuclear cell Anatomy 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 8
- 102000004895 Lipoproteins Human genes 0.000 claims description 7
- 108090001030 Lipoproteins Proteins 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 6
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 6
- 108010071619 Apolipoproteins Proteins 0.000 claims description 6
- 102000007592 Apolipoproteins Human genes 0.000 claims description 6
- 239000000816 peptidomimetic Substances 0.000 claims description 6
- 231100000673 dose–response relationship Toxicity 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims description 4
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims description 4
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims description 4
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 4
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 4
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 claims description 3
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims description 3
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 229960000815 ezetimibe Drugs 0.000 claims description 3
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
- 108010057973 CSL-111 Proteins 0.000 claims description 2
- -1 CSL-112 Proteins 0.000 claims description 2
- 108010016695 ETC216 Proteins 0.000 claims description 2
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 229960005370 atorvastatin Drugs 0.000 claims description 2
- 229960003765 fluvastatin Drugs 0.000 claims description 2
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 150000002948 pantothenic acids Chemical class 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- 208000032666 primary 1 hypoalphalipoproteinemia Diseases 0.000 claims description 2
- 229960000672 rosuvastatin Drugs 0.000 claims description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- PCLCDPVEEFVAAQ-UHFFFAOYSA-N BCA 1 Chemical compound CC(CO)CCCC(C)C1=CCC(C)(O)C1CC2=C(O)C(O)CCC2=O PCLCDPVEEFVAAQ-UHFFFAOYSA-N 0.000 claims 1
- 101150056798 bca-1 gene Proteins 0.000 claims 1
- 238000001802 infusion Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461988095P | 2014-05-02 | 2014-05-02 | |
| US61/988,095 | 2014-05-02 | ||
| PCT/IB2015/000854 WO2015173633A2 (en) | 2014-05-02 | 2015-04-30 | Hdl therapy markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515893A JP2017515893A (ja) | 2017-06-15 |
| JP2017515893A5 true JP2017515893A5 (enExample) | 2018-06-14 |
Family
ID=54147231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017508775A Pending JP2017515893A (ja) | 2014-05-02 | 2015-04-30 | Ｈｄｌ治療マーカー |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150316566A1 (enExample) |
| EP (1) | EP3137899A2 (enExample) |
| JP (1) | JP2017515893A (enExample) |
| KR (1) | KR20170003611A (enExample) |
| CN (1) | CN106488987A (enExample) |
| AU (1) | AU2015260929A1 (enExample) |
| BR (1) | BR112016025470A2 (enExample) |
| CA (1) | CA2947127A1 (enExample) |
| IL (1) | IL248601A0 (enExample) |
| MX (1) | MX2016014306A (enExample) |
| PH (1) | PH12016502167A1 (enExample) |
| RU (1) | RU2016144908A (enExample) |
| SG (1) | SG11201609084QA (enExample) |
| WO (1) | WO2015173633A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11840707B2 (en) * | 2016-05-31 | 2023-12-12 | Institut De Cardiologie De Montreal | Co-culture system and method for in vitro assessment of reverse cholesterol transport |
| WO2018029505A1 (en) * | 2016-08-11 | 2018-02-15 | Cerenis Therapeutics Holding Sa | Cer-001 therapy for treating familial primary hypoalphalipoproteinemia |
| ES2681124B1 (es) * | 2017-03-08 | 2019-06-19 | Fund Imdea Alimentacion | Usos medicos de la apolipoproteina a y de activadores de la misma |
| CN108913761B (zh) * | 2017-08-10 | 2022-01-18 | 施军平 | 一种用于筛查遗传性肝病的试剂盒 |
| WO2019043201A1 (en) * | 2017-09-01 | 2019-03-07 | Sorbonne Universite | TRANSCRIPTION FACTOR ZNF471 USED AS THERAPEUTIC AGENT AND BIOMARKER |
| CN107764890B (zh) * | 2017-10-16 | 2019-12-17 | 杭州先导医药科技有限责任公司 | 一种依折麦布对映异构体的区分检测方法 |
| WO2020185598A1 (en) * | 2019-03-08 | 2020-09-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for assessing cardiovascular disease or inflammatory disease risk using non-exchangeable lipid probe |
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
| EP4135838A1 (en) * | 2020-04-16 | 2023-02-22 | Abionyx Pharma SA | Cer-001 therapy for treating kidney disease |
| WO2021209808A1 (en) * | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
| US20240033322A1 (en) | 2020-04-16 | 2024-02-01 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
| WO2022046873A1 (en) | 2020-08-25 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Treatment of sepsis with pcsk9 and ldlr modulators |
| MX2023003877A (es) | 2020-10-01 | 2023-04-18 | Abionyx Pharma Sa | Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares. |
| EP4260062A1 (en) * | 2020-12-11 | 2023-10-18 | Helsingin Yliopisto | Method for determining a likelihood of a subject to respond to lipid lowering therapy |
| AU2022258815A1 (en) | 2021-04-15 | 2023-10-19 | Abionyx Pharma Sa | Use of lipid binding protein-based complexes in organ preservation solutions |
| CN113332423A (zh) * | 2021-05-26 | 2021-09-03 | 华中科技大学同济医学院附属协和医院 | 一种pcsk9抑制剂在心脏移植术后抗排斥反应中的应用 |
| WO2023194798A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
| EP4504150A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating eye diseases using lipid binding protein-based complexes |
| US20250360184A1 (en) | 2022-06-10 | 2025-11-27 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
| WO2023237927A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
| IL322074A (en) | 2023-01-13 | 2025-09-01 | Abionyx Pharma Sa | Treatment using a lipid-binding protein molecule |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| CN119534676B (zh) * | 2024-10-15 | 2025-08-15 | 中日友好医院(中日友好临床医学研究所) | 代谢标志物在制备监测pb神经毒性产品中的应用及制品 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| FR2704556B1 (fr) | 1993-04-30 | 1995-07-13 | Rhone Poulenc Rorer Sa | Virus recombinants et leur utilisation en thérapie génique. |
| CA2185450A1 (en) | 1994-03-22 | 1995-09-28 | Patrick Tso | Eating suppressant peptides |
| US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| US6258596B1 (en) | 1995-05-22 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Variants of apolipoprotein A-I |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| SE9603068D0 (sv) | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| SE9603303D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| SE9603304D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a compound |
| US6306433B1 (en) | 1997-08-12 | 2001-10-23 | Pharmacia Ab | Method of preparing pharmaceutical compositions |
| US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| ATE266672T1 (de) | 1998-12-30 | 2004-05-15 | Folke Tjerneld | Trennungsmethode unter verwendung von flüssig- flüssig partition |
| ATE384035T1 (de) | 1999-04-01 | 2008-02-15 | Esperion Therapeutics Inc | Ether-verbindungen, zusammensetzungen und ihre verwendung |
| GB9919713D0 (en) | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| EP1278767A4 (en) | 2000-04-12 | 2003-11-12 | Principia Pharmaceutical Corp | ALBUMIN FUSED PROTEINS |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2407083A1 (en) | 2000-04-21 | 2001-11-01 | Amgen Inc. | Apo-ai/aii peptide derivatives |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| IL155213A0 (en) | 2000-10-11 | 2003-11-23 | Esperion Therapeutics Inc | Ketone compounds and compositions for cholesterol management and related uses |
| US6703422B2 (en) | 2000-10-11 | 2004-03-09 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| IL155246A0 (en) | 2000-10-11 | 2003-11-23 | Esperion Therapeutics Inc | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| MXPA03003021A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
| CN1268641C (zh) | 2000-11-10 | 2006-08-09 | 普罗蒂奥制药公司 | 载脂蛋白类似物 |
| US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| US7033500B2 (en) | 2001-06-25 | 2006-04-25 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
| US6991727B2 (en) | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
| US20060060520A1 (en) | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
| CA2457840C (en) | 2001-08-20 | 2011-10-11 | Zlb Bioplasma Ag | Hdl for the treatment of stroke and other ischemic conditions |
| NZ532217A (en) | 2001-09-28 | 2006-12-22 | Esperion Therapeutics Inc | Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque |
| AUPR798901A0 (en) | 2001-09-28 | 2001-10-25 | Medvet Science Pty. Ltd. | Spheroidal hdl particles with a defined phospholipid composition |
| EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| US6930085B2 (en) | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| AU2003239489A1 (en) | 2002-05-17 | 2003-12-02 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
| BR0313069A (pt) | 2002-07-30 | 2007-07-17 | Esperion Therapeutics Inc | métodos de tratamento de um ser humano sofrendo de um distúrbio associado com dislipidemia e de tratamento de um paciente sofrendo de uma infecção, composição farmacêutica, complexo de lipìdeo-proteìna apoa-i animal não-humana, e, método de administração da composição |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DK2404890T3 (en) | 2003-01-23 | 2017-10-16 | Esperion Therapeutics Inc | Hydroxyl compounds and compositions for controlling cholesterol and related uses |
| US7375191B2 (en) | 2003-07-03 | 2008-05-20 | Lipid Science, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| JP4839221B2 (ja) | 2003-11-07 | 2011-12-21 | ジェイ ジェイ ファーマ，インコーポレイテッド | Ｈｄｌを高める併用療法用複合物 |
| TW200526778A (en) | 2003-11-14 | 2005-08-16 | Sembiosys Genetics Inc | Methods for the production of apolipoproteins in transgenic plants |
| ATE546734T1 (de) | 2003-12-05 | 2012-03-15 | Cleveland Clinic Foundation | Risikomarker für eine herzkreislaufkrankheit |
| EP1706131A4 (en) | 2003-12-15 | 2009-08-12 | Univ California | THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES |
| US7705177B2 (en) | 2003-12-24 | 2010-04-27 | Esperion Therapuetics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
| US7378396B2 (en) | 2004-08-11 | 2008-05-27 | The Cleveland Clinic Foundation | Therapeutic agents and methods for cardiovascular disease |
| EP1812474B1 (en) | 2004-10-15 | 2010-05-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multi-domain amphipathic helical peptides and methods of their use |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| ES2402823T3 (es) | 2006-06-01 | 2013-05-09 | Institut De Cardiologie De Montreal | Compuesto para uso en el tratamiento de estenosis valvular |
| CA2659655A1 (en) | 2006-08-08 | 2008-02-21 | Alan M. Fogelman | Salicylanilides enhance oral delivery of therapeutic peptides |
| US8541236B2 (en) | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
| MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
| US7956035B2 (en) | 2007-03-01 | 2011-06-07 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| US7749315B2 (en) | 2007-04-04 | 2010-07-06 | Xerox Corporation | Phase change inks containing colorant compounds |
| NZ598395A (en) | 2007-08-17 | 2013-07-26 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein A-I |
| CA2697957A1 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
| US8044021B2 (en) | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
| US8101565B2 (en) | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| EP2207800A1 (en) | 2007-10-19 | 2010-07-21 | Pronota NV | A protease-sensitive site in apolipoprotein a1, therapeutic and diagnostic implications |
| BRPI0818881A2 (pt) | 2007-10-23 | 2015-05-05 | Cleveland Clinic Foundation | Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo |
| CN102123722A (zh) | 2008-06-18 | 2011-07-13 | 加利福尼亚大学董事会 | 改进的胆固醇流出的肽介质 |
| US8378068B2 (en) | 2009-02-16 | 2013-02-19 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I mimics |
| DK3431076T3 (da) | 2009-06-10 | 2021-12-20 | Arbutus Biopharma Corp | Forbedret lipidformulering |
| EP2517013A4 (en) * | 2009-12-23 | 2013-07-17 | Artery Therapeutics Inc | DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT |
| EP3492085A1 (en) | 2010-06-30 | 2019-06-05 | CSL Limited | A reconstituted high density lipoprotein formulation and production method therof |
| DK2673296T3 (en) | 2011-02-07 | 2019-02-18 | Cerenis Therapeutics Holding Sa | LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF |
-
2015
- 2015-04-30 CN CN201580035131.6A patent/CN106488987A/zh active Pending
- 2015-04-30 EP EP15766230.5A patent/EP3137899A2/en not_active Withdrawn
- 2015-04-30 AU AU2015260929A patent/AU2015260929A1/en not_active Abandoned
- 2015-04-30 KR KR1020167033725A patent/KR20170003611A/ko not_active Withdrawn
- 2015-04-30 BR BR112016025470A patent/BR112016025470A2/pt not_active IP Right Cessation
- 2015-04-30 SG SG11201609084QA patent/SG11201609084QA/en unknown
- 2015-04-30 CA CA2947127A patent/CA2947127A1/en not_active Abandoned
- 2015-04-30 WO PCT/IB2015/000854 patent/WO2015173633A2/en not_active Ceased
- 2015-04-30 MX MX2016014306A patent/MX2016014306A/es unknown
- 2015-04-30 JP JP2017508775A patent/JP2017515893A/ja active Pending
- 2015-04-30 RU RU2016144908A patent/RU2016144908A/ru not_active Application Discontinuation
- 2015-04-30 US US14/700,351 patent/US20150316566A1/en not_active Abandoned
-
2016
- 2016-10-30 IL IL248601A patent/IL248601A0/en unknown
- 2016-11-02 PH PH12016502167A patent/PH12016502167A1/en unknown
-
2018
- 2018-03-07 US US15/914,087 patent/US20180203025A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515893A5 (enExample) | ||
| Landlinger et al. | The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE* 3Leiden. CETP mice | |
| McDade et al. | Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study | |
| RU2016144908A (ru) | Маркеры hdl-терапии | |
| Sabatine | PCSK9 inhibitors: clinical evidence and implementation | |
| Gaudet et al. | Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein (a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials) | |
| Gierman et al. | Metabolic stress–induced inflammation plays a major role in the development of osteoarthritis in mice | |
| de Munter et al. | High systemic levels of low-density lipoprotein cholesterol: fuel to the flames in inflammatory osteoarthritis? | |
| Graham et al. | Dyslipidemias in the prevention of cardiovascular disease: risks and causality | |
| Suominen et al. | Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis | |
| US20170326136A1 (en) | Treatment of Pain | |
| Ghosal et al. | The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features | |
| Ardelean et al. | Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia | |
| Reiter et al. | 1, 25-(OH) 2-vitamin D3 prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4−/− model | |
| Wang et al. | Therapeutic nuclear shuttling of YB-1 reduces renal damage and fibrosis | |
| JP2016538277A5 (enExample) | ||
| JP2017506626A5 (enExample) | ||
| JP2014513136A5 (enExample) | ||
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2017528427A5 (enExample) | ||
| Kougioumtzopoulou et al. | The role of radiotherapy in bone metastases: a critical review of current literature | |
| Kilic et al. | HMG-CoA reductase inhibition promotes neurological recovery, peri-lesional tissue remodeling, and contralesional pyramidal tract plasticity after focal cerebral ischemia | |
| Kerckhove et al. | Ethosuximide improves chronic pain-induced anxiety-and depression-like behaviors | |
| Markham | Evolocumab: first global approval | |
| Inoue et al. | Female sex hormones ameliorate arthritis in SKG mice |